ASX:KZA - Kazia joins GBM Agile

Wednesday, December 11, 2019 9:00 PM +00:00

ASX:KZA - Kazia joins GBM Agile0:0011:28
LIVEQuality1  AudioSubtitleDownloadSpeed1  
KAZIA THERAPEUTICS LIMITED
Dr James Garner

Kazia Therapeutics Limited (ASX: KZA), an Australian oncology-focused biotechnology company, is pleased to announce that it’s lead program, GDC-0084, has been selected to join GBM AGILE, an international, academic-led, multi-drug adaptive phase II / III study in glioblastoma.


Leave a Comment

Your email address will not be published

WEBCAST Calendar

  • 16 Mar

    02:00

    Working Together During Coronavirus Outbreak

    CISCO SYSTEMS
  • 16 Mar

    02:00

    FYI Resources DFS highlights low capital and operating costs for kaolin and HPA project

    FYI RESOURCES LIMITED
  • 16 Mar

    02:00

    Eli Lilly CEO talks partnering with AbCellera Biologics to co-develop a coronavirus cure 14.03.2020

    ELI LILLY AND COMPANY
  • 16 Mar

    02:00

    amaysim Australia Ltd (AYS) CEO & Managing Director, Peter O’Connell 11.03.2020

    AMAYSIM AUSTRALIA LIMITED
  • 16 Mar

    02:00

    2021 Ford Mustang Mach-E: Winter Testing All-Wheel Drive | Ford 13.03.2020

    FORD MOTOR COMPANY